Proactively manage your pharmacy inventory
Manage your formulary budget
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Modulators of cellular adhesion|
|Abstract:||The present invention provides compounds having formula (I): ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).|
|Inventor(s):||Shen; Wang (San Mateo, CA), Barr; Kenneth (Boston, MA), Oslob; Johan D. (Sunnyvale, CA), Zhong; Min (Foster City, CA)|
|Assignee:||SARcode Bioscience Inc. (Brisbane, CA)|
|Filing Date:||Feb 04, 2011|
|Claims:||1. A compound of the following structure: ##STR00215## or pharmaceutically acceptable salts thereof; wherein --C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the following structure: ##STR00216## R.sup.3A is hydrogen; R.sup.S is hydrogen; Ar.sub.2 is: ##STR00217## s is an integer of 1; each occurrence of R.sup.P1 is independently hydrogen, halogen, or -GR.sup.G1, wherein G is --SO.sub.2--, or --SO.sub.2NR.sup.G2--; and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; R.sup.B1, R.sup.B2 and R.sup.E are hydrogen; R.sup.4A and R.sup.4B are each Cl; L is C.dbd.O; and AR.sub.1 is ##STR00218## wherein R.sup.Q1 is independently hydrogen, OR.sup.Q3, OCF.sub.3, SR.sup.Q3, halogen, CN, isocyanate, NO.sub.2, CF.sub.3, NR.sup.Q3R.sup.Q4, --SO.sub.2R.sup.Q3, alkyl-NR.sup.Q3R.sup.Q4, alkyl-C(.dbd.O)--NR.sup.Q3R.sup.Q4, alkyl-C(.dbd.O)R.sup.Q3, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, or heteroalkylheteroaryl moiety, wherein each occurrence of R.sup.Q3 and R.sup.Q4 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and r is an integer from 0-6. |
2. The compound of claim 1, wherein R.sup.P1 is selected from the group consisting of halogen and -GR.sup.G1, wherein G is --SO.sub.2-- and R.sup.G1 is methyl.
3. The compound of claim 2, wherein R.sup.P1 is selected from the group consisting of F and SO.sub.2CH.sub.3.
4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
5. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or diluent.
6. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier or diluent.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.